Brazil: AGU defines role of ANVISA and INPI


Quick background for readers who are new to brazil patent scenario: In brazil, the pharmaceutical product and related patents’ grant (it is not much clear here; what kind of patent application are linked) is linked to its regulatory agency ANVISA (Brazilian National Health Surveillance Agency). The Brazilian Patent Office (INPI) will send the patent application files to ANVISA in order to obtain official approval, which will state reasons for giving or denying its approval. Related reading click here

In a recent decision,  Attorney general of union defines the role of ANVISA and INPI. According to AGU’s opinion, INPI will analyze the patentability requirement and ANVISA’s role will be restricted to evaluating safety and efficacy.

Nearly 145 pharmaceutical patent applications are pending due to the disagreement.

[patentlybiotech] [AGU’s press release translated] [Original press release]

Advertisements

About Guna

Interested to learn things around me
This entry was posted in Patent case and tagged , , , . Bookmark the permalink.

One Response to Brazil: AGU defines role of ANVISA and INPI

  1. Pingback: Brazil pharmacy | Selcer

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s